Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of
DUSA Pharmaceuticals, Inc. Shareholders
NEW YORK -- November 08, 2012
Kirby McInerney LLP is investigating potential claims against the Board of
Directors of DUSA Pharmaceuticals, Inc. (“DUSA” or the “Company”) (NASDAQ:
DUSA) related to the proposed acquisition of the Company by Sun Pharmaceutical
Industries Limited. Under the terms of the agreement, Sun Pharmaceutical will
commence a tender offer to acquire all of the outstanding common stock of DUSA
for $8.00 per share in cash, or approximately $230 million.
The investigation concerns whether the DUSA Board of Directors violated its
fiduciary duties by agreeing to this transaction and whether the proposed
$8.00 per share consideration adequately values DUSA common shares. The
average analyst price target for the Company’s shares is $8.33 per share, and
at least one analyst has set a price target of $9.50 per share – 17% above the
proposed acquisition price.
If you are a DUSA shareholder and wish to obtain additional information,
please contact J.Brandon Walker, Esq. by email at firstname.lastname@example.org, or by
telephone at (212) 699-1145 or (888) 529-4787.
Kirby McInerney LLP is a New York-based law firm concentrating in securities,
shareholder, whistleblower, antitrust and consumer litigation. For additional
information, please go to www.kmslaw.com.
Kirby McInerney LLP
J.Brandon Walker, Esq.
Press spacebar to pause and continue. Press esc to stop.